Liver and biliary tract cancer trials in India

In India 14 Also abroad 1314

14 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
Where
Belagavi, Hyderabad, Mumbai, Nashik, New Delhi, Varanasi
Age
18 years and over
People
286 worldwide
Run by
Jazz Pharmaceuticals
See details and how to joinNCT06282575 · EU 2023-508219-21-00
Phase 3Taking people
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
Where
Dehradun, Delhi, Kanpur, Kolkata, Mumbai, Vadodara, Varanasi
Age
18 years to 99 years
People
620 worldwide
Run by
AstraZeneca
See details and how to joinNCT06467357 · EU 2023-508057-19-00
Phase 3Taking people
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
Where
Ahmedabad, Bangalore, Binnāguri, Dehradun, Delhi, Hyderabad, Mumbai, Nashik, Vadodara
Age
18 years and over
People
1,220 worldwide
Run by
AstraZeneca
See details and how to joinNCT06921785 · EU 2024-518210-81-00
Phase 3Taking people
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
Where
Delhi, Hyderabad, Kolhāpur, Kolkata, Mumbai, Nashik, Surat
Age
18 years and over
People
1,100 worldwide
Run by
AstraZeneca
See details and how to joinNCT07221253 · EU 2025-523085-24-00
Phase 1Not yet taking people in India
Affordable Made-in-India Microspheres for Liver Cancer Therapy
Where
Bhubaneswar, Chandigarh, Delhi, Mumbai, Puducherry
Age
18 years to 90 years
People
18
Run by
Post Graduate Institute of Medical Education and Research, Chandigarh
See details and how to joinNCT07436988
No phaseTaking people
Phase II Trial of Immunonutrition in Hepatectomy
Where
Mumbai
Age
18 years to 90 years
People
100
Run by
Tata Memorial Centre
See details and how to joinNCT07395635
No phaseTaking people
Prospective Evaluation of 68Ga-FAPI PET in Biliary Cancers
Where
Mumbai
Age
18 years to 90 years
People
60
Run by
Tata Memorial Centre
See details and how to joinNCT07337850
No phaseTaking people
The Study of Association of Helicobacter Infections in Biliary Tract Cancers
Where
New Delhi
Age
18 years and over
People
250
Run by
Institute of Liver and Biliary Sciences, India
See details and how to joinNCT06909188
Phase 3Taking people
Trastuzumab Plus Chemotherapy vs Chemotherapy Alone in First-line HER2 Positive Advanced Biliary Tract Cancer Patients
Where
Bhubaneswar, Delhi, Mūllānpur, Mumbai, Muzaffarpur, Varanasi
Age
18 years to 99 years
People
220
Run by
Tata Memorial Centre
See details and how to joinNCT07062263
No phaseEnrolling by invitation
International Registry of Congenital Portosystemic Shunt (IRCPSS)
Where
Kochi, New Delhi
Age
1 day and over
People
500 worldwide
Run by
Prof. Valérie Mc Lin
See details and how to joinNCT06041906
Phase 3Taking people
Neoadjuvant Chemotherapy for Locally Advanced Gall Bladder Cancer : a Randomized Control Trial (NEOGB)
Where
Delhi
Age
18 years to 70 years
People
114
Run by
Rajiv Gandhi Cancer Institute & Research Center, India
See details and how to joinNCT06712420
Phase 2/3Taking people
Radiation Therapy in Unresectable Gall Bladder Cancer
Where
Mumbai
Age
18 years and over
People
249
Run by
Tata Memorial Centre
See details and how to joinNCT06214572
No phaseNot yet taking people in India
Comparative Study of Carvedilol Monotherapy Versus Combination Therapy With Endoscopic Variceal Ligation (EVL) for Primary Prophylaxis of Variceal Bleeding in Patients With Hepatocellular Carcinoma With High-Risk Esophageal Varices
Where
New Delhi
Age
18 years to 80 years
People
100
Run by
Institute of Liver and Biliary Sciences, India
See details and how to joinNCT06836778
No phaseTaking people
NGS in Gallbladder Cancer and Response to Treatment
Where
Varanasi
Age
18 years to 99 years
People
100
Run by
Banaras Hindu University
See details and how to joinNCT05404347